Who is sponsoring NCT04066374?

NCT04066374 is sponsored by The Cleveland Clinic.

What drugs are being tested in NCT04066374?

Interventions in NCT04066374: Peripheral Nerve Stimulation.

What condition does NCT04066374 study?

NCT04066374 studies Postoperative Pain.

Is NCT04066374 still recruiting?

NCT04066374 is currently completed. Last updated 9 July 2024.

Are results published for NCT04066374?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-07-09 · How we verify

NCT04066374

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility Study for Intrathoracic Nerve Stimulation

Completed NA Results posted Last updated 9 July 2024

What this trial tests

NA trial testing Peripheral Nerve Stimulation in Postoperative Pain in 10 participants. Completed in 11 June 2024.

Timeline

13 August 2019

Primary endpoint
9 January 2024

11 June 2024

Quick facts

Lead sponsor	The Cleveland Clinic
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	13 August 2019
Primary completion	9 January 2024
Estimated completion	11 June 2024
Sites	1 location across United States

Drugs / interventions tested

Peripheral Nerve Stimulation

Conditions studied

Postoperative Pain — all drugs for Postoperative Pain →

Sponsor

The Cleveland Clinic

Who can join

22 and older, any sex, with Postoperative Pain. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Pain as Measured by the Visual-analog Scale Primary · Baseline to 3 months

Pain level expressed by the study subject in the scale of 0 (no pain) to 10 (unbearable pain). Lower scores represent the better outcome.

Group	Value	95% CI
Treatment Arm	1	0 – 3

Freedom From Device Related Adverse Events Primary · up to 7 days

Freedom from device related adverse events (i.e., bleeding, infection, pneumothorax or arrhythmias)

Bleeding

Group	Value	95% CI
Treatment Arm	0

Infection

Group	Value	95% CI
Treatment Arm	1

Pneumothorax

Group	Value	95% CI
Treatment Arm	1

Arrhythmias

Group	Value	95% CI
Treatment Arm	0

Adverse events — posted to ClinicalTrials.gov

Time frame: Time of procedure to 3-months post-op visit. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Treatment Arm

Serious: 4/10 (40%)

Deaths: 0/10

Serious adverse events (6 terms)

Reaction	System	Treatment Arm
Pleural Effusion	Respiratory, thoracic and mediastinal disorders	—
Acute Kidney Injury	Renal and urinary disorders	—
COPD	Respiratory, thoracic and mediastinal disorders	—
Pneumothorax	Respiratory, thoracic and mediastinal disorders	—
Emphysema	Respiratory, thoracic and mediastinal disorders	—
Pneumonia	Respiratory, thoracic and mediastinal disorders	—

Other adverse events (4 terms — click to expand)

Reaction	System	Treatment Arm
Discomfort	General disorders	—
Discomfort	General disorders	—
Pleural Effusion	Respiratory, thoracic and mediastinal disorders	—
Abdominal Pain	Gastrointestinal disorders	—

Most-reported serious reactions: Pleural Effusion, Acute Kidney Injury, COPD, Pneumothorax, Emphysema, Pneumonia.

Data from ClinicalTrials.gov NCT04066374 adverse events section.

Sponsor's own description

The purpose of this study is to conduct an early clinical evaluation of safety and feasibility of peripheral nerve stimulation (PNS) of the intercostal nerves using an electrical lead placed in the thoracic cavity as a safe and effective method of pain control after cardiothoracic surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Peripheral Nerve Stimulation

Trials testing the same drug.

NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
NCT06702631 — Nitrous Oxide Neuroimaging · EARLY_PHASE1 · recruiting
NCT06113965 — Neural Operant Conditioning · NA · withdrawn
NCT06702904 — Evaluation of Neuroprosthesis with Sensory Feedback for Modulation of Phantom Limb Pain and Enhancing Quality of Life · NA · recruiting

Other The Cleveland Clinic trials

Trials by the same sponsor.

NCT07218198 — Clinical Decision Support Tool for the Treatment of Uncontrolled Hypertension · NA · not yet recruiting
NCT07442747 — Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS · NA · not yet recruiting
NCT07471464 — Centered Surgery - Preoperative Counseling and Patient Satisfaction · recruiting
NCT07073963 — Virtual Patient Groups for Sarcoidosis Associated Fatigue · NA · recruiting
NCT07363343 — Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04066374 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Cleveland Clinic
Last refreshed: 9 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04066374.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing